Barclays maintains an 'Overweight' on McKesson (MCK); Initial Thoughts on Court Order Delaying US Oncology Acquisition
Tweet Send to a Friend
Barclays maintains an 'Overweight' on McKesson (NYSE: MCK), PT $76.
Barclays analyst says, "From our discussions with the company, McKesson ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "From our discussions with the company, McKesson ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
